| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8657253 | Atherosclerosis Supplements | 2017 | 15 Pages |
Abstract
For the first time data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp(a) levels, progressive CVD and maximally tolerated lipid lowering medication. In addition LA treatments were found to be safe, exhibiting a low rate of side effects.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
V.J.J. Schettler, C.L. Neumann, C. Peter, T. Zimmermann, U. Julius, E. Roeseler, F. Heigl, P. Grützmacher, H. Blume,